Sponsors (8)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Introduced May 15, 2025 by Gary C. Peters · Last progress May 15, 2025
Requires the Secretary of Health and Human Services to maintain and regularly update an "Essential Medicines List" and to lead interagency work to assess, map, and visualize U.S. supply chains for those medicines. The law directs HHS to publish risk-assessment and mapping reports, identify supply‑chain vulnerabilities (including reliance on foreign suppliers and cybersecurity risks), and coordinate mitigation steps with other agencies; the Department of Defense must separately report every 180 days on drugs it purchased that were sourced or manufactured in the People’s Republic of China. Deadlines are measured from enactment (first updates and reports due within 180 days; mapping report due within 18 months; public risk report within 1 year) and recurring periodic reporting is required thereafter.
The bill improves visibility, coordination, and national-security preparedness for essential medicine supplies—reducing shortage risks and clarifying authorities—but does so at the cost of increased administrative and compliance burdens, potential commercial confidentiality losses, and the risk that publicly disclosed vulnerabilities could be exploited or cause short-term supply disruptions.
Hospitals, clinicians, and patients with chronic conditions will gain clearer, regularly updated visibility into which medicines are essential and at risk, enabling better preparedness, procurement planning, and fewer unexpected treatment disruptions.
Military planners, DOD, and policymakers will get clearer visibility into drugs critical for military readiness and dependencies on foreign inputs (including PRC links), supporting targeted stockpiling, procurement changes, and national-security mitigation actions.
States, suppliers, hospitals, and the public will benefit from greater transparency and a federal roadmap (including potential use of authorities like the Defense Production Act) that coordinates mitigation of essential medicine supply vulnerabilities.
Taxpayers, hospitals, industry, and federal staff may face increased administrative, reporting, and cybersecurity compliance costs to maintain the list, run analyses, and meet new disclosure and mapping requirements.
Public release or inadequate redaction of prioritized lists and supply-chain maps could reveal vulnerabilities or procurement details that adversaries or bad actors exploit, raising national-security and safety risks.
Publishing establishment locations, production amounts, or supplier links could expose trade secrets and commercial-confidential information, harming manufacturer competitiveness and risking supplier relationships.